Clinical trials: Pulmonary Tuberculosis
Tuberculosis, Pulmonary
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
- Trial name
- NCT05899400
- Testing
- Diascopic iON Image Analysis System
- Where
- Uganda
- Volunteers
- 400 people
- Sponsor
- Diascopic, LLC
Non - Tuberculosis Mycobacteria Lung Disease
NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy
Treatment of non - tuberculosis mycobacteria lung disease is challenging. The current treatment used is from 2007 American Thoracic Society guidelines recommended antibiotic combination therapy, which is lack of validation of…
- Trial name
- NCT03224065
- Testing
- Genotype detected through GenSeizer high-throughput gene capture technology
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Post Tuberculosis, Lung Disease
TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease
Post-Tuberculosis Lung Disease (PTLD) is defined as chronic respiratory impairment due to previous pulmonary TB. Children recovering from pulmonary TB undergo ongoing respiratory health challenges, including more frequent…
- Conditions
- Post Tuberculosis, Lung Disease, Functional Capacity, Spirometry
- Trial name
- NCT07451899
- Where
- Indonesia
- Volunteers
- 23 people
- Sponsor
- Universitas Padjadjaran
Pulmonary TB
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease…
- Trial name
- RIFAstrat (NCT07118696)
- Testing
- Extra 600mg of Rifampicin
- Volunteers
- 1,000 people
- Sponsor
- Hamilton Health Sciences Corporation
COVID-19
INTEGrating Ag-RDTs for COVID-19 in MNCH,HIV and TB Services in Cameroon and Kenya
Integration of antigen-detecting rapid diagnostic tests (Ag-RDT) for COVID-19 into services that provide care for vulnerable populations such as pregnant women, children, people with HIV infection, and patients with tuberculosis…
- Trial name
- INTEGRATE (NCT05382130)
- Testing
- Test all
- Where
- 2 sites in Cameroon, Kenya
- Volunteers
- 152,082 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Tuberculosis, Pulmonary
Impact of Malnutrition on Pharmacokinetic of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children (TB-Speed TB-PK)
TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in…
- Trial name
- NCT04972903
- Where
- 4 sites in Uganda, Zambia
- Volunteers
- 85 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Cystic Fibrosis
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
An increase in the prevalence of infections due to non-tuberculous mycobacteria (NTM) is observed in many countries and recent data suggest the circulation of dominant clones with a possibility of human-to-human contamination.
- Trial name
- CIMENT (NCT03312075)
- Testing
- Sputum and blood samples
- Where
- 14 sites in France
- Volunteers
- 848 people
- Sponsor
- University Hospital, Brest
Pulmonary Tuberculosis (TB)
ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)
The purpose of this study is to assess pharmacokinetic parameters of atorvastatin at different doses when combined with the standard first line tuberculosis (TB) treatment regimen in adults with drug sensitive pulmonary TB.
- Trial name
- NCT07303699
- Testing
- Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg
- Where
- 3 sites in Nigeria
- Volunteers
- 80 people
- Sponsor
- Obafemi Awolowo University Teaching Hospital
Tuberculosis, Pulmonary, Interferon-gamma Release Tests
IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection
The aim of this project is to analyze the potential contribution of IGRA test QuantiFERON-TB Gold In Tube test (QTF-GIT, Cellestis Limited, Carnegie, Victoria, Australia) in the diagnosis of tuberculosis (TB - active or latent)…
- Conditions
- Tuberculosis, Pulmonary, Interferon-gamma Release Tests, Tuberculin Test
- Trial name
- TBTubercolar (NCT02653404)
- Testing
- IGRA test (QTF-GIT)
- Where
- 3 sites in Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Siena
Tuberculosis, Pulmonary, Mycobacterium Tuberculosis Infection
Clinic-based Versus Hotspot-focused Active TB Case Finding
This five-year study will evaluate two strategies for conducting tuberculosis (TB) active case finding (ACF) and linkage to TB treatment or TB preventive therapy (TPT) in peri-urban Uganda.
- Trial name
- CHASE-TB (NCT05285202)
- Testing
- Active TB case finding with linkage to preventive therapy (ACF/TPT)
- Where
- Uganda
- Volunteers
- 146,539 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Tuberculosis
The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis
The investigators will evaluate the usefulness of QuantiFERON-TB Gold in-tube (QFT) in the diagnosis of active tuberculosis in young adults group, highly clinically suspected tuberculosis.
- Trial name
- NCT00982969
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Armed Forces Capital Hospital, Republic of Korea
Tuberculosis
Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries
The ERASE - TB study will be conducted in order to fill a critical unmet need for tuberculosis control. Persons who are in contact with an infectious TB case may become infected themselves.
- Trial name
- ERASE-TB (NCT04781257)
- Testing
- New test candidates
- Where
- 3 sites in Mozambique, Tanzania and 1 more
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Michael Hoelscher
Pulmonary Tuberculosis
Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) are two drug metabolizing enzymes. Antituberculosis drug isoniazid is acetylated by NAT2 and forms ultimately a nontoxic compound which is metabolized by CYP2E1 to a…
- Trial name
- NCT00834353
- Testing
- ATT
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Maulana Azad Medical College
Tuberculosis, Pulmonary
Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia
Tuberculosis ( TB ) remains a major global public health problems and actions to ensure the diagnosis and complete treatment of all cases is the priority for the control of this disease.
- Trial name
- DOTS (NCT01945905)
- Testing
- Intramural, Extramural
- Where
- Colombia
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Fundación FES
Cystic Fibrosis (CF), Mucoviscidosis
Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households
This multicenter, non-interventional case-control study investigates whether household environmental reservoirs, particularly water systems, are associated with non-tuberculous mycobacterial (NTM) infections in people with cystic…
- Conditions
- Cystic Fibrosis (CF), Mucoviscidosis, Non-Tuberculous Mycobacteria, Mycobacterium Abscessus Infection
- Trial name
- NTMecoCF (NCT07369414)
- Testing
- Multi-modal NTM diagnostic including PCR, WGS, culture
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Research Center Borstel
Tuberculosis, Pulmonary
Vitamin D Supplementation Effect In Children With Pulmonary Tuberculosis Treatment
This study aims to evaluate the vitamin D supplementation effect to improve clinical outcomes in children with pulmonary tuberculosis treatment.
- Trial name
- NCT05073965
- Testing
- Vitamin D
- Where
- Indonesia
- Volunteers
- 84 people
- Sponsor
- Universitas Padjadjaran
Tuberculosis, Multidrug-Resistant, Tuberculosis
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis…
- Conditions
- Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses, Mycobacterial Infections
- Trial name
- endTB-Q (NCT03896685)
- Testing
- Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule
- Where
- 10 sites in India, Kazakhstan and 4 more
- Volunteers
- 323 people
- Sponsor
- Médecins Sans Frontières, France
Pulmonary Tuberculosis Confirmation by Sputum Microscopy With or Without Culture
Bioaerosol Sampling in Suspected Pulmonary Tuberculosis
Tuberculosis (TB) is transmitted in bioaerosols containing Mycobacterium tuberculosis (Mtb). Mtb-containing bioaerosols are likely related to host infectiousness and central to ongoing TB transmission.
- Trial name
- NCT04241809
- Testing
- Bioaerosol Sampling
- Where
- South Africa
- Volunteers
- 102 people
- Sponsor
- Desmond Tutu HIV Foundation
Post Tuberculosis
Mechanisms, Biomarkers and Pulmonary Rehabilitation in Post-TB Lung Disease
Tuberculosis (TB) affects millions of people worldwide, and many individuals continue to experience long-term health problems even after completing TB treatment.
- Trial name
- AFTER-TB (NCT07731009)
- Testing
- Pulmonary rehabilitation
- Volunteers
- 760 people
- Sponsor
- Jose Antonio Dominguez Benitez
Tuberculosis
BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children
The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis.
- Trial name
- NCT07893444
- Testing
- 4-month FDC-based regimen, 3-month BDCZ regimen, Standard 6-month treatment regimen
- Where
- 13 sites in China
- Volunteers
- 90 people
- Sponsor
- Huashan Hospital